Secura Bio Appoints Charles R. Romp as Chief Executive Officer
Secura Bio, Inc., an integrated pharmaceutical company dedicated to advancing oncology therapies, has announced the appointment of Charles (Chip) R. Romp as its new Chief Executive Officer, succeeding Joseph (Joe) M. Limber. This strategic decision marks a pivotal moment for the company as it aims to enhance its growth trajectory and expand its global footprint.
Leadership Transition and Executive Insight
Jeffrey Ferrell, a member of the Board of Directors, expressed enthusiasm over Chip's appointment, noting, "We are excited to welcome Chip to the role of CEO at Secura Bio. During his time on the Board, he has provided valuable insights based on his extensive experience in leading commercial organizations. We look forward to leveraging his leadership as we realize our potential," he stated. Ferrell also acknowledged the significant contributions Limber made during his tenure.
Chip Romp's Vision for Secura Bio
In welcoming the opportunity, Mr. Romp shared his excitement about joining a talented team. "Having had the privilege to interact with the dedicated professionals at Secura Bio, I feel honored to take on this role. We are well-positioned to execute our strategic vision, focusing on acquiring innovative products and expanding our portfolio. My objective is to work closely with the team to build Secura into a dynamic global organization," he added.
Extensive Experience in the Pharmaceutical Sector
Chip Romp brings a wealth of experience to his new position, having over 25 years in the pharmaceutical industry, particularly in oncology and hematology. He previously held the role of Executive Vice President of Commercial U.S. at Seagen, Inc., where he played a pivotal role in overseeing the entire commercial structure of the company until its sale to Pfizer. Romp's leadership contributed significantly to the growth of prominent products such as ADCETRIS® and TUKYSA®.
Before joining Seagen, Romp held senior sales leadership positions at Genentech, Inc., where he worked on notable oncology and immunology products. His educational background includes a Bachelor of Arts from the University of Florida and an MBA from Saint Leo University in Florida.
About Secura Bio, Inc.
Secura Bio is committed to bringing impactful oncology therapies to patients globally. Their flagship product, COPIKTRA®, is currently approved to treat multiple B-cell malignancies and is under development for other indications such as peripheral T-cell lymphoma. The company is actively engaging in clinical studies to explore additional therapeutic combinations.
The Role of Athyrium Capital Management
Athyrium Capital Management, which holds the majority stake in Secura Bio, focuses on investment opportunities within the healthcare sector. Established in 2008, Athyrium manages over $4.6 billion in capital and has a robust track record in various asset classes, supporting companies like Secura Bio. Their strategic investment approach covers biopharma, medical devices, and healthcare IT.
Frequently Asked Questions
Who is the newly appointed CEO of Secura Bio?
The new CEO of Secura Bio is Charles (Chip) R. Romp, who brings over 25 years of experience in the pharmaceutical industry.
What are the main responsibilities of the new CEO at Secura Bio?
Chip Romp will lead the strategic vision of the company, focusing on acquiring products and expanding the product portfolio in oncology.
What significant experience does Chip Romp bring to Secura Bio?
He has extensive experience in leading commercial organizations, having previously worked at Seagen, Inc. and Genentech, Inc., overseeing significant oncology products.
What is COPIKTRA® and its relevance to Secura Bio?
COPIKTRA® is Secura Bio's key product, approved for treating multiple B-cell malignancies, indicating the company’s focus on oncology therapies.
What role does Athyrium Capital Management play in Secura Bio?
Athyrium Capital Management is a majority shareholder of Secura Bio, focusing on investment opportunities in the healthcare sector, which supports Secura's growth strategies.
